Loading
A phase 2 trial of Cadonilimab, Gemcitabine, Leucovorin (folinic acid) and Oxaliplatin in pancreatic ductal adenocarcinoma, run by Akeso, now recruiting.
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer is a phase 2 interventional study registered as NCT05859750 by Akeso, with 78 participants planned, started 2023-05-25 and due to reach its primary completion in 2025-06. Interventions recorded: AK104, Gemcitabine, Nab-Paclitaxel, Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate and Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Akeso, Bispecific antibodies, Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Leucovorin (folinic acid), Oxaliplatin, Gemcitabine, Metastatic pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Akeso, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/